PHARMACY

Report: Mylan to move HQ

BY Alaric DeArment

PITTSBURGH — Generic drug maker Mylan is looking for a bigger place to call home, according to published reports.

The Pittsburgh Business Times reported that Mylan was planning to move from its current 96,000-sq.-ft. headquarters in Southpointe, a development in the Pittsburgh suburb of Cecil Township, to a 250,000-sq.-ft. building nearby.

The new headquarters is under construction, the newspaper reported.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Certification, advanced training programs prepare pharmacy technicians for workforce

BY Alaric DeArment

WASHINGTON — The Pharmacy Technician Certification Board said that its certification and advanced training programs, developed by the Pharmacy Technician Workforce Coalition of the Triad, support the development of a highly skilled pharmacy technician workforce in North Carolina.

The coalition’s two-year associate of applied science degree training program includes curriculum that covers pharmaceutical calculations, medical terminology, computer systems and critical thinking skills. The PTCB said the program prepares a “highly trained” and PTCB-certified pharmacy technician workforce to take on new medication distribution and administrative tasks. The coalition comprises health-system pharmacy employers and local community colleges.

“Graduates of the AAS program are qualified, have an appreciation for the work pharmacists do and are eager to support and take ownership in patient care services,” Novant Health VP pharmacy services and chief pharmacy officer Michael Nnadi said. “We have seen unprecedented response from community colleges.”

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Shire’s Lialda receives FDA approval

BY Alaric DeArment

PHILADELPHIA — The Food and Drug Administration has approved a drug made by Shire for treating ulcerative colitis, the British drug maker said Monday.

Shire announced the approval of Lialda (mesalamine) delayed-release tablets for the maintenance of remission in patients with the disease.

The drug was already approved for inducing remission in patients with ulcerative colitis, an inflammatory disease that affects the colon and causes chronic inflammation, sores and ulcers.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES